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Nanoparticles  functionalized  with
IGFBP7-sdAb injected  into  mouse
bind to glioma.
Superparamagnetic  iron  oxide  pro-
vides opportunities  for  application  of
glioma SWI.
SWI  showed  better  contrast-to-noise
ratio for  tumor  rim  and  core  than  gra-
dient echo.
SWI  combined  with  targeted
nanoparticles provides  improved
glioma visualization.
g  r  a  p  h  i c  a  l  a  b  s  t  r  a  c  t
SWI  of the  glioma  before  (A)  and  (B)  after  injection  of  the  targeted  contrast  agent.
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a  b  s  t  r  a  c  t
Background:  Glioma  is  the most  common  and  most  difﬁcult  to treat  brain  cancer.  Despite  many  efforts
treatment,  efﬁcacy  remains  low.  As  neurosurgical  removal  is  the  standard  procedure  for glioma,  a  method,
allowing  for both  early  detection  and  exact  determination  of  the  location,  size  and  extent  of  the  tumor,
could  improve  a patient’s  positive  response  to therapy.
New method:  We  propose  application  of susceptibility  weighted  molecular  magnetic  resonance  imaging
using,  targeted  contrast  agents,  based  on superparamagnetic  iron  oxide  nanoparticles,  for  imaging  of the,
glioma  rim, namely  brain-tumor  interface.  Iron  oxide  attached  to the targeted  cells increases,  suscepti-argeted  contrast agents
lioma
bility  differences  at the  boundary  between  tumor  and  normal  tissue,  providing  the  opportunity,  to  utilize
susceptibility  weighted  imaging  for improved  tumor  delineation.  We  investigated  potential,  enhance-
ment  of the  tumor-brain  contrast,  including  tumor  core  and  rim  when  using  susceptibility,  weighted
MRI  for  molecular  imaging  of  glioma.
Results: There  were  signiﬁcant  differences  in contrast-to-noise  ratio before,  12  and  120  min  after  contrast,
agent  injection  between  standard  gradient  echo  pulse  sequence  and susceptibility  weighted  molecular,
magnetic  resonance  imaging  for the  core-brain,  tumor  rim-core  and  tumor  rim-brain  areas.
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Comparison  with  existing  methods:  Currently,  the  most  common  MRI  contrast  agent  used  for  glioma
diagnosis is a non-speciﬁc,  gadolinium-based  agent  providing  T1-weighted  enhancement.  Susceptibility-
weighted magnetic,  resonance  imaging  is  much  less  efﬁcient  when  no  targeted  superparamagnetic
contrast agents  are,  used.
Conclusion: The  improved  determination  of  glioma  extent  provided  by  SWI  offers  an  important  new  tool


























































Brain tumors are among the most devastating cancers. Among
hem glioblastoma is both the most common and most difﬁcult
o treat (Rock et al., 2012; Colman et al., 2009; Ohagak et al.,
005). The mean survival rate is about 50 weeks and has essen-
ially remained unchanged over the past 30 years (Ellegala et al.,
003; Aghi et al., 2005). This poor prognosis may  be related to
nsufﬁcient differentiation of normal brain and tumor, thus result-
ng in incomplete resection. The determination of exact tumor
ize and its extent is important for accurate treatment planning,
oth for surgery and adjuvant radiotherapy (Cai and Chen, 2008).
he surgical removal of malignant glioma remains the standard
f practice, even though it has had only limited success due to
ocal recurrence. The glioma rim (i.e. tumor-brain interface) is com-
rised of peritumoral parenchyma (Villalba et al., 2008; Blasiak
t al., 2010) and provides the oxygenation and nutritional supply
eeded for tumor growth and to support the tumor invasion into
he surrounding normal brain tissue (Vajkoczy et al., 1999). The
nvaded cells and the gradient-driven diffusely invasive nature of
liomas are believed to be responsible for tumor recurrence follow-
ng surgery near the resection boundary (Kelly et al., 1987; Villalba
t al., 2008; Jiang et al., 2008). Complete tumor removal is par-
icularly challenging in MRI-guided treatment because standard
1-weighted or gadolinium-enhanced MRI  used for glioma diag-
osis fail to precisely detect the tumor boundaries (Schwartz et al.,
006; Cai and Chen, 2008; LaConte et al., 2007; Wang et al., 2001).
 clinical report comparing CT and MR  imaging abnormalities to
istopathology was able to establish four tumor zones (Kelly et al.,
987): zone 1 corresponding to tumor necrosis, zone 2 consisting
f solid tumor tissue with increased vascularity and zones 3 and
 corresponding to inﬁltrating tumor outside the area enhanced
n CT and MR  imaging. Changes in signal intensity using diffusion-
eighted imaging, indicating restricted water diffusion, have been
sed to diagnose brain abscess. Molecular glioma MRI  in an ani-
al model (Gambarota et al., 2006), using targeted contrast agents,
ased on superparamagnetic nanoparticles (NP) conjugated to an
ntibody (Tomanek et al., 2012; Runge et al., 1984) have been used
o target a speciﬁc tumor cell marker, potentially allowing more
peciﬁc diagnosis. The most frequently used superparamagnetic
Ps in molecular MRI  are based on iron oxide (Lawaczeck et al.,
004), (Huber and Synthesis, 2005; Santra et al., 2005; Tomanek
t al., 2012), that reduces T2 and T2* relaxation times, providing
umor-speciﬁc contrast, and thus increase the capability of MRI  to
etect tumor boundaries (Gambarota et al., 2008; Oh et al., 2005).
ron attached to the tumor cells or tumor vasculature increases sus-
eptibility differences at the boundary between tumor and normal
issue, providing the opportunity to utilize susceptibility weighted
maging (SWI) for improved tumor delineation. SWI  has been used
or diagnosis of various neurological conditions (Lupo et al., 2009;
aacke et al., 2004; Lee et al., 1999; Tong et al., 2008). In particu-
ar, SWI  can detect vasculature disorders and micro-hemorrhages
lthough its capability has not been yet fully investigated. Several
nvestigators have shown that SWI  can visualize presumed intra-
umoral microvasculature and necrosis (Grabner et al., 2012; Tan
t al., 2000; Pinker et al., 2008; Seghal et al., 2010; Moenninghoff
t al., 2010).4  The  Authors.  Published  by  Elsevier  B.V.  
In our study we used gradient echo (GE) data to create SWI  to
investigate potential improvement in visualization of iron content
in the tumor and in particular in the at the tumor-brain interface
corresponding to zone 2 described by Kelly et al. (1987), using the
molecular MRI  of a mouse glioma model. The MRI  of the mouse
brain was  performed before and after intravenous injection of the
targeted contrast agent.
2.  Materials and methods
2.1.  Tumor model
Details  of the tumor model have been previously described
(e.g. Blasiak et al., 2010; Ellegala et al., 2003). Brieﬂy, the
U87MGdEGFRvIII cell line (U87MG), provided by the Ludwig Insti-
tute for Cancer Research (La Jolla, CA, USA), was used. Six CD-1
nude mice (male, 6 weeks old, Charles River, Canada) were used for
studies. Animals were anesthetized by intraperitoneal injection of
a mixture of ketamine (150 mg/kg) and xylazine (10 mg/kg) and
placed in a stereotactic head frame (Kopf Instruments, Tujunga,
CA). Tumor cells were inoculated by injection of approximately
5 × 104 U87MGdEGFRvIII glioma cells, suspended in a total volume
of 2–3 L, intracerebrally into the frontal lobe of each mouse with
a chromatography syringe at a depth of 2.5–3 mm (1 mm anterior
and 1.8 mm lateral to the bregma) (Ellegala et al., 2003). Subse-
quently, the bony calvarium was sealed by a droplet of bone wax to
prevent reﬂux and the skin was  sutured. After the surgery, animals
were allowed to recover from anesthesia and were placed in their
cages. All animal procedures were approved by the local Animal
Care Committee.
2.2.  MRI protocol
The  MRI  sessions started 10 days after cell inoculation when
tumor was about 2 mm in diameter. A 9.4 T/21 cm horizontal bore
magnet (Magnex, UK) with a Biospec console (Bruker, Germany)
was used. A volume (3 cm diameter, 2.5 cm long) radio-frequency
coil was placed over the animal’s head covering the region of inter-
est, namely the frontal cortices. For in vivo MRI  experiments, a 2 mg
Fe/ml concentration of the functionalized contrast agent was  used
(Gambarota et al., 2008) and 200 l of the contrast agent was slowly
(2–3 min) administered via tail vein cannula made of drawn down
PE10 polyethylene tubing using a 0.5-ml insulin syringe with a 27-G
ﬁxed needle (vehicle, 0.9% saline).
The axial T2*-weighted GE images were collected at the level
of the tumor before, 12 min and 2 h after contrast injection with
the following parameters: FOV = 2 × 2 cm,  slice thickness of 1 mm,
matrix size 128 × 128, TR = 50 ms,  50 kHz bandwidth and a 15
degree ﬂip angle; echo time (TE) was  7 ms,  10 accumulations.
The  SW images were processed as described by Haacke et al.
(2009). The raw time-domain data were zero ﬁlled to 512 × 512
prior to 2D Fourier transformation and a phase image generated in
the frequency domain. A high-pass ﬁlter was  used to remove the
Open access under CC BY-NC-SA license.low-spatial-frequency phase as follows: the central 48 × 48 points
were used to create a phase image which was then used to subtract
out the low-frequency phase components of the original 512 × 512
phase image. An image mask was  then calculated to multiply the
































CFig. 1. Selection of regions of interest for CNR calculatio
12 × 512 magnitude image using the following rule designed to
nhance pixels of positive phase:
f (x, y) =  − ϕ(x, y)

for  > ϕ(x, y) > 0
f (x, y) = 1, otherwise
This mask was multiplied with the original magnitude image
our times to produce an image with enhanced contrast.
.3.  Contrast agent synthesis and injection
Commercially available iron oxide NPs were used (Nanotech-
cean, USA). The NP consisted of a 20 nm mean diameterFe3O4core,
mbedded in a dextran matrix, with a hydrodynamic diameter of
bout 63 nm (Corot et al., 2006; Suwa et al., 1998). The NPs were
unctionalized with IGFBP7-sdAb (Hamzah et al., 2009), an anti-
ody that binds with high speciﬁcity to the glioma vasculature.
ntravenous tail injection was used to deliver the contrast agent.
.4.  Selection of regions of interest (ROI)
To analyze the tumor rim contrast-to-noise ratio (CNR), three
egions of interest (ROIs) were selected for quantitative comparison
Fig. 1): tumor rim, tumor core, normal brain. Noise was  calculated
s average signal intensity outside of the brain.
The tumor rim was deﬁned by the hypo-intense peripheral
dges of the tumor (Fig. 1A). The tumor core was deﬁned as the
nner homogenous section of the tumor excluding the rim (Fig. 1B).
he area of normal brain was selected from the artifact free area
ocated in the contralateral hemisphere (Fig. 1C). Average signal
ntensities (SI) and standard deviations (SD) for each ROI were cal-
ulated (Marevisi, NRC, Canada). CNR for each ROI was  calculated
o quantify the differences in visualization of the rim and tumor
ccording to the formulae:
NR(1) = SI(normal brain) − SI(core)
Noise
NR(2) = SI(normal brain) − SI(rim)
Noise
NR(3) = SI(core) − SI(rim)
Noise
Statistical analysis was performed using ANOVA and 2-tailed
tudent paired t test. Data were reported as mean ± SD.
.5. Histology
At  the end of the MRI  experiment, mice were sacriﬁced by intrac-
rdiac perfusion with heparinized saline and their brains were
xcised and ﬁxed in formalin. Coronal sections (50 m)  were pro-
uced using a Vibratome sectioning instrument (Ted Pella, Redding,
A, USA). Brain tissue sections were examined for the presence ofmor rim (A), tumor core (B), normal brain (C), noise (D).
iron nanoparticles by an Iron Stain Kit (Sigma) as per manufac-
turer’s instructions. Brieﬂy, the sections were incubated for 30 min
at room temperature with iron staining solution (a 1:1 mixture
of 4% potassium ferrocyanide and 4% hydrochloric acid). Sections
were then washed in deionized water and incubated for 3 min  with
1% pararosaniline solution diluted 1/50 in water, followed by addi-
tional washing with deionized water. Tissue sections were then
mounted on Superfrost Plus microscope slides (Fisher Scientiﬁc,
Nepean, ON, Canada), cover slipped using mounting media and
examined under a light microscope.
3. Results
Fig. 2 shows SWI  of a mouse bearing brain tumor before (2A), 12
(2B) and 120 min (2C) after injection of the contrast agent. Respec-
tive GE images are shown for comparison in the bottom row. The
tumor is not clearly visible before injection in both SWI  and GE
(Fig. 2A and D). SWI  12 and 120 min  after injection show higher
tumor and rim contrast than GE MRI.
The SW image (Fig. 3) shows noticeable visual post-contrast
enhancement. The tumor core, and in particular tumor boundaries,
are visibly darker when compared to the pre-contrast images.
CNR  for brain tissue and tumor core in SW and GE images
before, 12 and 120 min  after injection of the contrast agent is
shown in Fig. 4. The results show signiﬁcant (p < 0.01) increase
of CNR in SWI  (from −4.3 ± 7.8 to 17.4 ± 10.2) before and 12 min
post injection; no signiﬁcant (p > 0.05) increase between before and
120 min  after (−4.3 ± 7.7and 2.5 ± 1.9 respectively) and signiﬁcant
(p < 0.01) decrease of CNR between 12 and 120 min after injection
(from 17.4 ± 10.2 to 2.5 ± 1.9). GE shows CNR values of −0.9 ± 2.8,
6.3 ± 5.3, 2.9 ± 1.4 corresponding to signiﬁcant intensity changes
for before/12 min  after and before/120 min  after (p < 0.05 in both
cases). There were no signiﬁcant changes between 12 and 120 min
after injection (p > 0.05). A comparison of CNR for brain tissue and
tumor core between SWI  and GE showed no signiﬁcant differences
before and 120 min  after injection (p > 0.05). There was a signiﬁcant
difference 12 min  after the injection (p < 0.05) when CNR was  about
3 times higher in SWI  than in GE images (17.4 ± 10.2 and 6.3 ± 5.3).
Negative CNR (−4.3 ± 7.7; normal brain darker) between brain
tissue and tumor core was  observed before injection in SW
images while CNR became positive 12 and 120 min after injec-
tion (17.4 ± 10.2; 2.5 ± 1.9). In GE negative CNR was also observed
before injection (−0.9 ± 2.8), and become positive 12 and 120 min
after injection (6.3 ± 5.3; 2.9 ± 1.4).
CNR for normal brain tissue and tumor rim in SW and GE
images before, 12 and 120 min  after injection of the contrast
agent is shown in Fig. 5. The results show signiﬁcant (p < 0.05)
increase of CNR in SWI  before and 12 min  after injection (from
15.1 ± 10.9 to 35.3 ± 10.7), before and 120 min after (15.1 ± 10.9
and 20.1 ± 10.1)and between 12 and 120 min  after injection
(35.3 ± 10.7 and 20.1 ± 10.1) The difference in CNR in GE was not
signiﬁcant (p > 0.05) for before/12 min  after, before/120 min  after
and 12/120 min  after injection respectively with the correspond-
ing CNR values of 7.8 ± 10.9; 16.8 ± 5.2; 11.8 ± 4.6. A comparison of
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Fig. 2. SW (top row) and GE (bottom row) MR images of a mouse bearing brain tumor before (A, D), 12 (B, E) and 120 min  (C, F) after injection of the targeted contrast agent.
Fig. 3. Magniﬁed SWI  of the glioma including rim and core obtained before (A) and 12 min  (B) after injection of the targeted contrast agent.Fig. 4. A comparison of CNR for brain tissue and tumor core using SW and GE images before, 12 and 120 min  after injection of the contrast agent.
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Fig. 5. A comparison of CNR for brain tissue and tumor rim in SW and GE images before, 12 and 120 min  after injection of the targeted contrast agent.























Fig. 7. Microscopic images of mouse glioma sections obtained using Prussian BlueFig. 6. A comparison of CNR for tumor core and tumor rim in SW an
NR for normal brain tissue and tumor rim between SWI  and GE
howed signiﬁcant differences before (p < 0.04), 12 min  (p < 0.01)
nd 120 min  (p < 0.03) after injection
CNR for tumor rim and tumor core in SW and GE images before,
2 and 120 min  after injection of the contrast agent is shown in
ig. 6. The results show no signiﬁcant (p > 0.05) change of CNR (from
9.4 ± 9.7 to17.7 ± 5.6) in SWI  before and 12 min  after injection;
o signiﬁcant (p > 0.05) change between before and 120 min  after
from 19.4 ± 9.7 to 17.6 ± 10.0) and no signiﬁcant (p > 0.05) change
f CNR between 12 and 120 min  after injection (from 17.7 ± 5.6 to
7.6 ± 10.0). GE shows similar tendency (p > 0.05) for before/12 min
fter, before/120 min  after and 12/120 min  after respectively with
he corresponding CNR values 8.7 ± 10.5, 10.5 ± 2.8 and 8.9 ± 4.4.
 comparison of CNR between SWI  and GE for tumor core and rim
howed signiﬁcant (p < 0.05) differences at each time point. CNR for
umor rim and corein both SWI  and GE was positive at each time
oint.
Histological images (Fig. 7) of the brain sections obtained 24 h
fter contrast injection conﬁrmed higher accumulation of the iron
xide within the rim when compared to the tumor core and non-
umor region. Our results have not provided information if the
umor cells or tumor microvasculature were present outside the
im. However the extend of the tumor has been a topic of recent
tudies by others (Wang and Zhou, 2012; Iqbal et al., 2010).
staining collected after the last MRI  session (24 h after intravenous injection of the
targeted contrast agent). The images show accumulation of the iron within the
tumor (as indicated by the black arrow). Blue spots indicate iron, red – nuclei and
pink – cytoplasm. (For interpretation of the references to color in this ﬁgure legend,
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. Discussion
The results showed that targeted NPs are not accumulating
omogenously throughout the tumor region. Twelve min  after con-
rast injection CNR was improved for the tumor rim and brain tissue
s well for the tumor core and brain tissue in both SW and GE images
ndicating higher accumulation of the NPs in the tumor rim and
ore region than in the brain tissue (Fig. 2). This effect was  less
vident in GE than in SW images as demonstrated by quantitative
NR analysis. There were signiﬁcant differences in CNR before, 12
nd 120 min  after contrast agent injection between GE and SWI  for
he core-brain, tumor rim-core and tumor rim-brain areas, except
umor core-brain CNR before and 120 min  after injection.
The higher CNR for SWI  after NP injection when compared with
E for each of the measured regions is caused by enhanced suscep-
ibility effects in phase sensitive SWI  (Haacke et al., 2004, 2009;
einstein et al., 2010). The decrease of signal from the normal
rain, tumor core and rim 12 and 120 min  after contrast injection is
aused by the NPs accumulation (Weinstein et al., 2010) in all these
egions. The highest CNR between tumor rim and normal brain in
oth SWI  and GE images is caused by the highest accumulation of
Ps in tumor rim followed by the accumulation in tumor core and
n normal brain.
The  above observations are associated with signiﬁcant hyper-
ascularization and involvement of peritumoral parenchyma
djacent to the tumor growth. The angiogenesis induces hypervas-
ularization, which provides oxygenation and nutritional supply
eeded for tumor growth and supporting the tumor ability to
nvade the surrounding parenchyma (Vajkoczy et al., 1999). Chronic
verproduction of angiogenic factors, such as VEGF, in malignant
lioma leads to uncontrolled development of new blood vessels,
ncreased vascular permeability and tumor growth (Blasiak et al.,
010). It is evident from the result of this study that the vasculature-
ich rim is abnormal in SWI  appearance compared to the tumor
ore and normal brain regions. This effect is enhanced in SWI, as
t is particularly sensitive to the presence of blood vessels with
uperparamagnetic contrast agents. This improved determination
f the glioma extent provided by SWI  may  be important in both
iagnosis and treatment, as it would allow detection of cells out-
ide the grossly visible mass, invading locally or metastasizing
istantly (Swanson et al., 2003). Of particular interest may  be the
pplication of contrast agent enhanced SWI  to intraoperative MRI.
ontrast agents injected prior to surgical intervention may  enhance
isualization in surgical planning, intraoperative MRI  or on MRI
cquired during dissection. This could increase the precision of
umor resection at the vessel-rich tumor-brain interfaces. However
he lack of the approved targeted NPs in patients remains a current
imitation.
The rim enhancement has been observed by other authors
n both T2- and T1-weighted imaging with Gd enhancement for
RI of abscesses and multiple sclerosis (Schwartz et al., 2006).
he enhancement was attributed to the generation of para-
agnetic free radicals by macrophages (Haimes et al., 1989)
n either abscesses or multiple sclerosis plaques (Yetkin and
aughton, 1995). However, hypointensity was found to be non-
peciﬁc (Schwartz et al., 2006). Elevated iron levels have also
een reported in many neurodegenerative disorders, including
arkinson’s disease, Alzheimer’s disease, Huntington’s disease and
myotrophic lateral sclerosis.
High-spatial  resolution SWI  provides complementary informa-
ion on the brain vasculature, hemorrhage, and iron content due
o its sensitivity to susceptibility differences (Haacke et al., 2004;
auscher et al., 2005). Our results showed that SWI  is also useful
or the evaluation of tumor extent in a murine model and shows
romise for evaluating clinical brain tumors by enhanced visual-
zation of heterogeneity.e Methods 226 (2014) 132–138 137
5. Conclusions
The study demonstrates that improved visualization of glioma
structure can be achieved using SWI  in combination with targeted
iron oxide contrast agents. This technique can provide assessment
of the microvascularity inside and beyond the tumor margin in
the glioma animal model at 9.4 T by providing improved CNR for
tumor rim, core and normal tissue. This enables improved glioma
identiﬁcation, characterization and detection that could be used
for enhanced diagnosis, improved treatment, treatment monitor-
ing of gliomas and possibly for a better understanding of other
cerebrovascular diseases.
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